In colorectal cancer, consensus molecular subtypes (CMSs) and colorectal cancer typing (CRCAssigner) based on mRNA expression profiles predict the efficacy of bevacizumab and anti-EGFR in RAS wild-type advanced colorectal cancer (14, 15). This evidence concerns the gene EGFR and colorectal cancer.